Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 — nearly double the $100 million it originally planned — after investor demand exceeded available shares by more than tenfold. Shares priced at $17, opened at $22.60, and closed at $22.00, a 29% first-day gain that gave the company a market capitalization of roughly $1.53 billion. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. CEO and founder Yuling Luo told Reuters the company plans to use the proceeds to expand into cancer, cardiology, and other major disease areas. The company reported $74.2 million in revenue for fiscal year 2025 — nearly triple the prior year — giving public investors a baseline for measuring commercial growth against the IPO's lofty expectations.
The blockbuster debut was part of a historic biotech listings day: obesity-drug developer Kailera Therapeutics also priced its IPO on April 17, raising $625 million — the largest biotech IPO since Moderna's $600 million raise in 2018 — and surging 63% on its first day of trading. Analysts cited both offerings as evidence that the window for life sciences public listings had materially reopened. Alamar's success marks a sharp reversal from 2021–2023, when three protein-analysis firms that went public saw their valuations collapse. What changed: Thermo Fisher Scientific's $3.1 billion acquisition of competitor Olink in early 2024 validated the technology's commercial potential, and breakthroughs in blood-based Alzheimer's testing proved that protein detection could solve real clinical problems, not just generate research data.
